切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2019, Vol. 07 ›› Issue (02) : 141 -144. doi: 10.3877/cma.j.issn.2095-655X.2019.02.015

所属专题: 文献

综述

肝细胞癌临床诊断及其适配体应用的研究现状
陈意飞1, 夏伟2, 顾晨3, 杨生妹3,()   
  1. 1. 225007 扬州大学附属医院急诊医学科
    2. 225007 扬州大学附属医院肝胆胰外科
    3. 225009 扬州大学生物科学与技术学院生物化学系
  • 收稿日期:2019-01-04 出版日期:2019-05-26
  • 通信作者: 杨生妹
  • 基金资助:
    扬州市十三五科教强卫工程(ZDRC2018016)

Research of diagnosis and application of Aptamer in hepatocellular carcinoma

Yifei Chen1, Wei Xia2, Chen Gu3, Shengmei Yang3,()   

  1. 1. Department of Emergency, the Affiliated Hospital of Yangzhou University, Yangzhou 225002, China
    2. Department of Hepatobilliary Surgery, the Affiliated Hospital of Yangzhou University, Yangzhou 225002, China
    3. Department of Biochemistry, College of Bioscience and Biotechnology, Yangzhou University, Yangzhou 225009, China
  • Received:2019-01-04 Published:2019-05-26
  • Corresponding author: Shengmei Yang
  • About author:
    Corresponding author: Yang Shengmei, Email:
引用本文:

陈意飞, 夏伟, 顾晨, 杨生妹. 肝细胞癌临床诊断及其适配体应用的研究现状[J/OL]. 中华诊断学电子杂志, 2019, 07(02): 141-144.

Yifei Chen, Wei Xia, Chen Gu, Shengmei Yang. Research of diagnosis and application of Aptamer in hepatocellular carcinoma[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(02): 141-144.

肝细胞癌是临床上最常见的消化系统恶性肿瘤之一,是导致癌症相关死亡的第二大病因。肝细胞癌的发生机制比较复杂,临床治疗手段有限,预后不佳。适配体的筛选和建立,可用于分子生物学细胞检测、影像分析以及靶向治疗,是肝细胞癌诊治新的希望。适配体相关研究从肝细胞癌细胞的检测、分子标志物检测出发,形成了良好的开端,为进一步实现干扰信号通路、介导基因、靶向治疗,提供了新的方向。本综述兼顾了肝细胞癌的临床诊断现状,重点阐述了适配体技术原理及其在肝细胞癌诊断中的研究进展。

Hepatocellular carcinoma (HCC) is one of the most common malignancies in digestive system and the second leading cause of cancer-related death. It has complicated pathogenesis, limited clinical treatments and poor prognosis. The screening and establishment of Aptamers can be used for molecular biological cell detection, image analysis and targeted therapy so as to be a new hope for the diagnosis and treatment of hepatocellular carcinoma. Relevant studies have made a good start from the detection of hepatocellular carcinoma cells and molecular markers, providing a new direction for the further progression of interfering signal pathways, mediating genes and targeted therapy.This review concentrates on the clinical diagnosis of hepatocellular carcinoma, the principle of Aptamer experiment and its progress in the diagnosis of hepatocellular carcinoma.

图1 指数富集法进化系统原理示意图
[1]
Chen W, Zheng R, Baade PD,et al.Cancer statistics in China,2015 [J].CA Cancer J Clin,2016,66(2):115-132.
[2]
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma[J].Nat Rev Dis Primers,2016(2):16018.
[3]
Schmidt S, Follmann M, Malek N,et al.Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma [J].J Gastroenterol Hepatol,2011,26(12):1779-1786.
[4]
Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J].Nat Genet,2015,47(5):505-511.
[5]
European association for the study of the liver, european organisation for research and treatment of cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma [J].J Hepatol,2012,56(4):908-943.
[6]
Verslype C, Rosmorduc O, Rougier P,et al.Hepatocellular carcinoma:ESMO-ESDO clinical practice guidelines for diagnosis,treatment and follow-up [J].Ann Oncol,2012,23(Suppl7):41-48.
[7]
黄天从,李新丰,刘德鑫,等.甲胎蛋白异质体在老年肝癌诊断与肝动脉化疗栓塞治疗中的临床意义[J/CD].中华诊断学电子杂志,2017,5(4):243-24
[8]
周文瑞,李新丰,林奇忆,等.血清甲胎蛋白异质体、高尔基体糖蛋白-73及甲胎蛋白检测在老年人原发性肝癌的诊断价值[J/CD].中华诊断学电子杂志,2016,4(4):222-225.
[9]
Yu SJ.A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world:2010-2016 [J].Clin Mol Hepatol,2016,22(1):7-17.
[10]
Marrero JA, Feng Z, Wang Y,et al.Alpha-fetoprotein,des-gamma carboxyprothrombin,and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma [J].Gastroenterology,2009,137(1):110-118.
[11]
Yu B, Yang X, Xu Y,et al.Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas [J].J Hepatol,2009,50(5):948-957.
[12]
Shen Q, Fan J, Yang XR,et al.Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma:a large-scale,multicentre study [J].Lancet Oncol,2012,13(8):817-826.
[13]
Lin XJ, Chong Y, Guo ZW,et al.A serum microRNA classifier for early detection of hepatocellular carcinoma:a multicentre,retrospective,longitudinal biomarker identification study with a nested case-control study [J].Lancet Oncol,2015,16(7):804-815.
[14]
Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy [J].Cancer Discov,2016,6(5):479-491.
[15]
Zhou J, Huang A, Yang XR.Liquid biopsy and its potential for management of hepatocellular carcinoma [J].J Gastrointest Cancer,2016,47(2):157-167.
[16]
Sun YF, Xu Y, Yang XR,et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection [J].Hepatology,2013,57(4):1458-1468.
[17]
Huang A, Zhang X, Zhou SL,et al.Plasma circulating cellfree DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma [J].J Cancer,2016,7(13):1798-1803.
[18]
Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment:RNA ligands to bacteriophage T4 DNA polymerase[J].Science,1990,249(4968):505-510.
[19]
Ellington AD, Szostak JW.In vitro selection of RNA molecules that bind specific ligands[J].Nature,1990,346(6287):818-822.
[20]
Ahmadyousefi Y, Malih S, Mirzaee Y,et al.Nucleic acid Aptamers in diagnosis of colorectal cancer[J].Biochimie,2019(156):1-11.
[21]
Lu B, Wang J, Zhang J,et al.Screening and verification of ssDNA Aptamers targeting human hepatocellular carcinoma[J].Acta Biochim Biophys Sin (Shanghai),2014,46(2):128-135.
[22]
Chen H, Yuan CH, Yang YF,et al.Subtractive Cell-SELEX selection of DNA Aptamers binding specifically and selectively to hepatocellular carcinoma cells with high metastatic potential[J].Biomed Res Int,2016 (2016):5735869.
[23]
Wang FB, Rong Y, Fang M, et al. Recognition and capture of metastatic hepatocellular carcinoma cells using Aptamer-conjugated quantum dots and magnetic particles[J].Biomaterials,2013,34(15):3816-3827.
[24]
Du J, Hong J, Xu C,et al.Screening and Identification of ssDNA Aptamer for Human GP73[J].Biomed Res Int,2015 (2015):610281.
[25]
Dong L, Tan Q, Ye W, et al. Screening and identifying a novel ssDNA Aptamer against alpha-fetoprotein using CE-SELEX[J].Sci Rep,2015(5):15552.
[26]
Lee KA, Ahn JY, Lee SH,et al.Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in hepatocellular carcinoma (HCC)[J].Sci Rep,2015(5):10897.
[1] 中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[2] 丁丁, 杨云川, 马翔, 马中正, 霍俊一, 周磊. 术前C-反应蛋白-白蛋白-淋巴细胞比值在肝细胞癌预后中的价值评估[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 261-265.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[7] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[8] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[9] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[10] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[11] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[12] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[13] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[14] 王向前, 李清峰, 陈磊, 丘文丹, 姚志成, 李熠, 吴荣焕. 姜黄素抑制肝细胞癌索拉非尼耐药作用及其调控机制[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 729-735.
[15] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 407-449.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?